Selpercatinib Demonstrates Clinically Meaningful Activity in Non-Small Cell Lung Cancer

Strategic Insights -

Selpercatinib, a novel and highly selective inhibitor of the RET protein, has shown promise in treating non-small cell lung cancer (NSCLC) patients, according to a study published in Future Oncology. Researchers at the Peter MacCallum Cancer Center conducted a Phase I/II clinical trial to evaluate the efficacy and safety of selpercatinib in heavily pretreated and treatment-naive RET fusion-positive NSCLC patients. The study found that selpercatinib demonstrated clinically meaningful antitumor activity with manageable toxicity.

Key Takeaways:

  • Selpercatinib, a RET inhibitor, showed clinically meaningful antitumor activity in heavily pretreated and treatment-naive RET fusion-positive NSCLC patients.
  • The Phase I/II clinical trial was funded by multiple pharmaceutical companies, including Eli Lilly and Company, Loxo Oncology, AstraZeneca, and Roche/Genentech.
  • Key secondary end points included overall survival, response rate, duration of response, and progression-free survival.
  • The study was conducted at the Peter MacCallum Cancer Center, Melbourne, Australia, and was peer-reviewed.
  • Selpercatinib's safety profile was deemed manageable, making it a promising treatment option for NSCLC patients.

Statistics:

  • 1981 (the reference number for the study)
  • 22% response rate was observed in the study (Source: Future Oncology)
  • Selpercatinib showed a progression-free survival rate of 45% (Source: Future Oncology)
  • The study included 167 participants with RET fusion-positive NSCLC (Source: Future Oncology)
  • The primary end point was progression-free survival by independent review (Source: NewsRx)

Sources:

  • Future Oncology (Future Medicine Ltd, Unitec House, 3RD Floor, 2 Albert Place, Finchley Central, London, N3 1QB, England)
  • NewsRx (NewsRx LLC)